CORRECTION ANNOUNCEMENT: ACORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE
January 19, 2016 04:19 ET
|
Biotie Therapies Oyj
TURKU, Finland, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Correction to Biotie Therapies Corp.'s stock exchange release issued on 19 January 2016 at 9:45 a.m. This correction concerns only the English...
CORDA ANNOUNCES A RECOMMENDED CASH TENDER OFFER FOR ALL SHARES, ADSs AND OTHER EQUITY INSTRUMENTS IN BIOTIE
January 19, 2016 02:51 ET
|
Biotie Therapies Oyj
TURKU, Finland, Jan. 19, 2016 (GLOBE NEWSWIRE) -- Acorda Therapeutics, Inc. ("Acorda") and Biotie Therapies Corp. ("Biotie" or the "Company") have today entered into a combination agreement...
Biotie to Present at the upcoming Stifel 2015 Healthcare Conference
November 10, 2015 06:19 ET
|
Biotie Therapies Oyj
TURKU, Finland, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) today announced that Timo Veromaa, President and Chief Executive Officer, is scheduled to present at the...
Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease
July 21, 2015 02:07 ET
|
Biotie Therapies Oyj
TURKU, Finland, July 21, 2015 (GLOBE NEWSWIRE) -- Biotie (Nasdaq Helsinki BTH1V; NASDAQ: BITI) announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a...
Biotie announces agreement with FDA on a Special Protocol Assessment for tozadenant Phase 3 study
May 25, 2015 02:04 ET
|
Biotie Therapies Oyj
TURKU, Finland, May 25, 2015 (GLOBE NEWSWIRE) -- Biotie Therapies has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 study of...
Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis
March 31, 2015 02:12 ET
|
Biotie Therapies Oyj
TURKU, Finland, March 31, 2015 (GLOBE NEWSWIRE) -- Biotie Therapies Corp ("Biotie") announces the start of patient enrolment into the Phase 2a clinical study evaluating BTT1023, Biotie's fully human...
Biotie provides portfolio update on tozadenant
February 20, 2015 02:15 ET
|
Biotie Therapies Oyj
TURKU, Finland, Feb. 20, 2015 (GLOBE NEWSWIRE) -- Biotie announces further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease...
Biotie: BTT1023 receives positive opinion for Orphan Drug Designation from COMP
February 17, 2015 03:35 ET
|
Biotie Therapies Oyj
TURKU, Finland, Feb. 17, 2015 (GLOBE NEWSWIRE) -- The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has in its February meeting issued a positive opinion...
BIOTIE ANNOUNCES START OF SYN120 PHASE 2A TRIAL IN PARKINSON'S DISEASE DEMENTIA AND PROVIDES OUTLOOK UPDATE FOR NEAR TERM PIPELINE EVENTS
December 23, 2014 02:35 ET
|
Biotie Therapies Oyj
TURKU, Finland, Dec. 23, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies Corp. ("Biotie") announces the start of the Phase 2a clinical study of SYN120, a 5-HT6/5-HT2A antagonist, in patients with...
BIOTIE: UK'S NICE ISSUES POSITIVE FINAL GUIDANCE FOR SELINCRO(r)
November 26, 2014 06:41 ET
|
Biotie Therapies Oyj
TURKU, Finland, Nov. 26, 2014 (GLOBE NEWSWIRE) -- Biotie Therapies (Biotie) announces that the National Institute for Health and Care Excellence (NICE), the United Kingdom's health technology...